ArticleJournal of health economics and outcomes research2025
Cost Savings Associated With Fully Automated Digital Cognitive Behavioral Therapy for Insomnia Disorder (SleepioRx): A Matched Control Study of US Patients.
Article in Journal of health economics and outcomes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insomnia affects up to one-third of US adults and is a significant health challenge with an estimated economic burden of up to $100 billion annually. Cognitive behavioral therapy (CBT) for insomnia (CBT-I) is the recommended first-line treatment, but access is limited due to a shortage of trained therapists. Digital CBT-I offers an effective alternative that may enhance accessibility and reduce higher healthcare costs associated with insomnia. Objective: To evaluate the US healthcare cost-savings of digital CBT-I compared with standard-of-care control. Methods: A retrospective difference-in-differences analysis compared 1-year preinitiation and post-initiation healthcare costs for 11 027 individuals receiving SleepioRx (FDA-cleared digital CBT treatment for insomnia disorder) compared with 1:1 exact matched controls with insomnia receiving standard care (n = 10 770). Commercial and Medicare claims were adjusted for comorbidities, index year, and baseline utilization. Results: Digital CBT-I was associated with statistically significant mean annual total cost savings of Discussion: Digital CBT-I was associated with substantial cost savings for payers. The integration of guideline-concordant treatment through digital delivery into standard care pathways offers a promising strategy to address the clinical and economic challenges of insomnia, supporting more efficient resource allocation. Conclusions: Findings suggest that implementing digital CBT-I at scale may lead to decreased costs for healthcare payers, relative to the current standard of care, while improving access to effective insomnia treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.